Rua Bioscience (RUA) H1 2026 earnings summary

Executive summary

• Revenue for the six months ended 31 December 2025 was $1,333,773, up 92% year-over-year, driven by new product launches and expanded international sales in five key markets: Germany, Australia, New Zealand, Czech Republic, and the UK.

• Net loss after tax was $1,793,429, a slight improvement from $1,802,255 in the prior year period.

• Significant capital was raised through a rights offer and share placement, strengthening liquidity.

• Continued execution of a capital-light strategy focused on genetics, distribution, and outsourcing manufacturing.

Financial highlights

• Revenue increased to $1,333,773 from $693,829 year-over-year.

• Net operating cash outflow was $1,520,360, improved from $1,942,997 in the prior year.

• Operating loss was $1,652,487, compared to $1,760,949 in the prior year.

• Cash and cash equivalents rose to $2,166,289 from $241,421 at 30 June 2025.

• Inventory write-downs totaled $102,373, up from $13,150 year-over-year.

Outlook and guidance

• Management forecasts sufficient cash to meet commitments if growth targets are achieved, with a focus on delivering revenue growth and differentiated offerings across five markets.

• Plans include further product expansion in Australia, Germany, Czechia, and New Zealand, and establishing genetics in Canada and trial crops in Australasia.

• Ongoing efforts to sell the Gisborne facility, with proceeds to reduce debt and support operations.

• Optimism about future opportunities and commitment to stakeholder value.